Read more

November 11, 2020
2 min watch
Save

VIDEO: ‘The great debate’ on JAK-inhibitor use in RA at ACR 2020

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, summarized “The Great Debate” at ACR 2020

Vibeke Strand, MD, from Stanford University School of Medicine, argued kinase (JAK) inhibitors should be used before biologics after a patient with rheumatoid arthritis experiences methotrexate failure, whereas Michael E. Weinblatt, MD, from Brigham and Women's Hospital, argued against using JAK-inhibitors prior to biologics, according to DiRenzo.

Reference

  • Strand V, Weinblatt ME. Session: 2F008. Presented at: ACR Convergence 2020; November 5-9, 2020 (virtual meeting).